Umifenovir: A Broad-Spectrum Antiviral Agent
Discover the science behind Umifenovir's efficacy against influenza, COVID-19, and Zika virus.
Get a Quote & SampleProduct Core Value
Umifenovir
Umifenovir, also known as Arbidol, is a synthetic antiviral drug primarily used for influenza treatment in Russia and China. Its unique dual mechanism involves blocking viral envelope fusion with host cell membranes and regulating immune responses. This broad-spectrum activity extends to various viruses, making it a subject of interest for treating emerging infectious diseases.
- Explore the detailed mechanism of action of Umifenovir in blocking viral fusion, a key aspect of its antiviral strategy.
- Investigate the clinical relevance of Umifenovir for COVID-19 treatment, examining the available research and its potential.
- Understand how Umifenovir demonstrates efficacy in inhibiting Zika virus replication through various in vitro studies.
- Learn about the pharmacokinetic properties and safety profile of Umifenovir, crucial factors for drug development.
Key Advantages of Umifenovir
Broad-Spectrum Efficacy
Umifenovir exhibits broad-spectrum antiviral activity, effectively inhibiting influenza A and B viruses, coronaviruses, and Zika virus, positioning it as a versatile therapeutic option.
Dual Mechanism of Action
The drug's efficacy stems from its dual action: it blocks viral entry by targeting hemagglutinin and also modulates the immune system, offering a comprehensive approach to combating viral infections.
Potential for Repurposing
The established use of Umifenovir for influenza and its demonstrated in vitro activity against other viruses like SARS-CoV-2 highlight its potential for drug repurposing in the face of new viral threats.
Key Applications
Influenza Treatment
Umifenovir is a primary treatment for influenza, effectively reducing symptoms and recovery time, making it a crucial tool in managing seasonal flu outbreaks.
COVID-19 Research
Early research has explored Umifenovir's potential against SARS-CoV-2, with in vitro studies showing inhibitory effects that warrant further investigation for COVID-19 treatment.
Zika Virus Inhibition
Studies demonstrate Umifenovir's ability to inhibit Zika virus replication, particularly by blocking viral attachment and entry, offering a potential therapeutic avenue for Zika infections.
Other Viral Infections
The broad-spectrum nature of Umifenovir suggests potential efficacy against other enveloped viruses, contributing to the ongoing research in antiviral drug development.